Michael Pearson, Valeant Pharmaceuticals International (Bloomberg) This Valeant Pharmaceuticals International sell-off is starting to get ugly. Shares of the fast-growing, acquisitive drug peddler plummeted another 19 percent Wednesday — after briefly falling as much as